Plasma cell disorders
Light-chain (AL) amyloidosis
BA, Economics: Northwestern University, 2010
MD: University of Illinois at Chicago, 2014
Resident: Vanderbilt University Medical Center, 2014-2017
Hematology/Oncology Fellow: Vanderbilt University Medical Center, 2017-2020
Clinical Assistant Professor: University of North Carolina, 2020 – Present
Research and clinical interests:
I am both a hematologist and medical oncologist, as well as a clinical researcher. My primary areas of clinical and research interest are plasma cell disorders such as multiple myeloma and light chain (AL) amyloidosis. I have interests in improving our ability to predict outcomes and responses to therapy, as well as in conducting clinical trials both of therapeutics and novel supportive care approaches for patients with plasma cell disorders. I also work on ways to leverage the electronic health record to answer important clinical questions in the area of plasma cell disorders and am involved in international registry efforts to understand the impacts of the COVID-19 pandemic on patients with cancer.
- Rivera DR, Peters S, Panagiotou OA, Shah DP, Kuderer NM, Hsu CY, Rubinstein SM, Lee BJ, Choueiri TK, de Lima Lopes G, Grivas P, Painter CA, Rini BI, Thompson MA, Arcobello J, Bakouny Z, Doroshow DB, Egan PC, Farmakiotis D, Fecher LA, Friese CR, Galsky MD, Goel S, Gupta S, Halfdanarson TR, Halmos B, Hawley JE, Khaki AR, Lemmon CA, Mishra S, Olszewski AJ, Pennell NA, Puc MM, Revankar SG, Schapira L, Schmidt A, Schwartz GK, Shah SA, Wu JT, Xie Z, Yeh AC, Zhu H, Shyr Y, Lyman GH, Warner JL. Utilization of COVID-19 treatments and clinical outcomes among patients with cancer: A COVID-19 and Cancer Consortium (CCC19) cohort study. Cancer Discov. 2020 Jul 22:CD-20-0941. doi: 10.1158/2159-8290.CD-20-0941. PubMed PMID: 32699031.
- Chen EC*, Rubinstein SM*, Soto C, Bombardi R, Day S, Myers L, Zaytsev A, Majedi M, Cornell RF, Crowe J. Diverse patterns of antibody variable gene repertoire disruption in patients with light chain (AL) amyloidosis. PLOS One. Accepted for publication, June 22, 2020. doi: 10.1371/journal.pone.0235713. PubMed PMID: 32634163. (*=contributed equally)
- Kuderer NM, Choueiri TK, Shah DP, Shyr Y, Rubinstein SM, Rivera DR, Shete S, Hsu CY, Desai A, de Lima Lopes G Jr, Grivas P, Painter CA, Peters S, Thompson MA, Bakouny Z, Batist G, Bekaii-Saab T, Bilen MA, Bouganim N, Larroya MB, Castellano D, Del Prete SA, Doroshow DB, Egan PC, Elkrief A, Farmakiotis D, Flora D, Galsky MD, Glover MJ, Griffiths EA, Gulati AP, Gupta S, Hafez N, Halfdanarson TR, Hawley JE, Hsu E, Kasi A, Khaki AR, Lemmon CA, Lewis C, Logan B, Masters T, McKay RR, Mesa RA, Morgans AK, Mulcahy MF, Panagiotou OA, Peddi P, Pennell NA, Reynolds K, Rosen LR, Rosovsky R, Salazar M, Schmidt A, Shah SA, Shaya JA, Steinharter J, Stockerl-Goldstein KE, Subbiah S, Vinh DC, Wehbe FH, Weissmann LB, Wu JT, Wulff-Burchfield E, Xie Z, Yeh A, Yu PP, Zhou AY, Zubiri L, Mishra S, Lyman GH, Rini BI, Warner JL. COVID-19 and Cancer Consortium. Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study. Lancet, 2020 Jun 20;395(10241):1907-1918. doi: 10.1016/S0140-6736(20)31187-9. PubMed PMID: 32473681.
- Rubinstein SM, Steinharter JA, Warner JL, Rini BI, Peters S, Choueiri TK. The COVID-19 & Cancer Consortium (CCC19): a collaborative effort to understand the effects of COVID-19 on patients with cancer. Cancer Cell, accepted for publication Apr 29, 2020. doi: 10.1016/j.ccell.2020.04.018. PubMed PMID: 32454025.
- Cornell RF, Goldhaber SZ, Engelhardt BG, Moslehi J, Jagasia M, Harrell S, Rubinstein SM, Hall R, Wyatt H, Piazza G. Primary prevention of venous thromboembolism with apixaban for multiple myeloma patients treated with immunomodulatory agents. Br J Hematology. Published online before print, April 21, 2020. doi: 10.1111/bjh.16653. PubMed PMID: 32314352.
- Weaver AB, Rubinstein SM, Cornell RF. Hyperviscosity syndrome in paraprotein secreting conditions including Waldenstrom macroglobulinemia. Front Oncol, accepted for publication Apr 25, 2020 10:815. doi: 10.3389/fonc.2020.00815. PubMed PMID: 32509586.
- Oke O, Sethi T, Goodman S, Phillips S, Decker I, Rubinstein S, Concepcion B, Horst S, Jagasia M, Kassim A, Harrell SL, Langone A, Lenihan D, Rawling KT, Slosky D, Cornell RF. Outcomes from autologous hematopoietic cell transplantation versus chemotherapy alone for the management of light chain amyloidosis. Biol Blood Marrow Transplant. 2017 Sep;23(9):1473-1477. doi: 10.1016/j.bbmt.2017.05.020. PubMed PMID: 28546074.8. Rubinstein S, Cornell RF, Du L, Concepcion B, Goodman S, Harrell S, Horst S, Lenihan D, Slosky D, Fogo A, Langone A. Novel pathologic scoring tools predict end-stage kidney disease in light chain (AL) amyloidosis. Amyloid. 2017 Sep;24(3):205-211. doi: 10.1080/13506129.2017.1360272. PubMed PMID: 28758811.